Aclaris Therapeutics, Inc. (0H8T.L)
USD 3.14
(6.34%)
USD 3.14
(6.34%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 12.14 Million USD | -88.21% |
| 2022 | 102.94 Million USD | 52.67% |
| 2021 | 67.43 Million USD | 35.22% |
| 2020 | 49.86 Million USD | -45.2% |
| 2019 | 91 Million USD | 6.65% |
| 2018 | 85.33 Million USD | 18.02% |
| 2017 | 72.29 Million USD | 62.72% |
| 2016 | 44.43 Million USD | 119.0% |
| 2015 | 20.28 Million USD | 137.76% |
| 2014 | 8.53 Million USD | 62.32% |
| 2013 | 5.25 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 14.18 Million USD | -55.32% |
| 2024 Q2 | 4.95 Million USD | -65.1% |
| 2023 Q3 | 30.96 Million USD | -7.81% |
| 2023 Q1 | 31.37 Million USD | 11.19% |
| 2023 FY | 127.69 Million USD | 24.04% |
| 2023 Q2 | 33.59 Million USD | 7.06% |
| 2023 Q4 | 31.76 Million USD | 2.56% |
| 2022 Q2 | 24.85 Million USD | 21.8% |
| 2022 FY | 102.94 Million USD | 52.67% |
| 2022 Q4 | 28.21 Million USD | -23.26% |
| 2022 Q3 | 36.76 Million USD | 47.94% |
| 2022 Q1 | 20.4 Million USD | -3.04% |
| 2021 Q2 | 13.76 Million USD | 8.7% |
| 2021 Q1 | 12.66 Million USD | 147.51% |
| 2021 Q3 | 19.95 Million USD | 44.95% |
| 2021 Q4 | 21.04 Million USD | 5.46% |
| 2021 FY | 67.43 Million USD | 35.22% |
| 2020 Q1 | 7.78 Million USD | -2.04% |
| 2020 FY | 49.86 Million USD | -45.2% |
| 2020 Q2 | 5.76 Million USD | -26.04% |
| 2020 Q3 | 4.67 Million USD | -18.78% |
| 2020 Q4 | 5.11 Million USD | 9.36% |
| 2019 Q3 | 7.11 Million USD | -73.45% |
| 2019 Q1 | 7.69 Million USD | 50.57% |
| 2019 FY | 91 Million USD | 6.65% |
| 2019 Q4 | 7.95 Million USD | 11.8% |
| 2019 Q2 | 26.79 Million USD | 248.22% |
| 2018 Q4 | 5.1 Million USD | -6.99% |
| 2018 FY | 85.33 Million USD | 18.02% |
| 2018 Q3 | 5.49 Million USD | 41.34% |
| 2018 Q1 | 17.64 Million USD | -29.47% |
| 2018 Q2 | 3.88 Million USD | -77.96% |
| 2017 Q1 | 12.55 Million USD | 9.45% |
| 2017 Q2 | 14.83 Million USD | 18.15% |
| 2017 Q3 | 18.42 Million USD | 24.16% |
| 2017 Q4 | 25 Million USD | 35.75% |
| 2017 FY | 72.29 Million USD | 62.72% |
| 2016 FY | 44.43 Million USD | 119.0% |
| 2016 Q4 | 11.47 Million USD | 7.3% |
| 2016 Q3 | 10.69 Million USD | -16.91% |
| 2016 Q2 | 12.87 Million USD | -1.29% |
| 2016 Q1 | 13.03 Million USD | 170.63% |
| 2015 Q1 | 2.62 Million USD | 0.81% |
| 2015 FY | 20.28 Million USD | 137.76% |
| 2015 Q3 | 10.63 Million USD | 309.87% |
| 2015 Q4 | 4.81 Million USD | -54.68% |
| 2015 Q2 | 2.59 Million USD | -1.11% |
| 2014 Q4 | 2.6 Million USD | -2.25% |
| 2014 Q1 | 1.63 Million USD | 0.0% |
| 2014 Q2 | 1.63 Million USD | 0.0% |
| 2014 Q3 | 2.66 Million USD | 62.86% |
| 2014 FY | 8.53 Million USD | 62.32% |
| 2013 FY | 5.25 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | 95.091% |
| Dynavax Technologies Corporation | 219.14 Million USD | 94.46% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 97.705% |
| Perrigo Company plc | 1.52 Billion USD | 99.206% |
| Illumina, Inc. | 3.81 Billion USD | 99.682% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 99.882% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 97.308% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.97% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 99.409% |
| Heron Therapeutics, Inc. | 120.65 Million USD | 89.938% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 99.569% |
| Unity Biotechnology, Inc. | 44.66 Million USD | 72.819% |
| Waters Corporation | 943.51 Million USD | 98.713% |
| Biogen Inc. | 5.2 Billion USD | 99.767% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 94.691% |
| Evolus, Inc. | 189.75 Million USD | 93.602% |
| Adicet Bio, Inc. | 152.03 Million USD | 92.014% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 91.478% |
| bluebird bio, Inc. | 240.23 Million USD | 94.946% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 95.535% |
| FibroGen, Inc. | 398.11 Million USD | 96.95% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 99.426% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | 12.715% |
| Homology Medicines, Inc. | 9.87 Million USD | -22.947% |
| Geron Corporation | 70.44 Million USD | 82.764% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 99.326% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 97.161% |
| Myriad Genetics, Inc. | 600.1 Million USD | 97.977% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 87.959% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 97.799% |
| Zoetis Inc. | 2.76 Billion USD | 99.561% |
| Abeona Therapeutics Inc. | 48.5 Million USD | 74.968% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 98.886% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 99.305% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 99.746% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 68.991% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 98.443% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 95.596% |
| Verastem, Inc. | 92.08 Million USD | 86.815% |
| Nektar Therapeutics | 190.9 Million USD | 93.64% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 97.451% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 99.108% |
| OPKO Health, Inc. | 574.68 Million USD | 97.887% |
| Exelixis, Inc. | 1.58 Billion USD | 99.235% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 99.24% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 96.706% |
| Anavex Life Sciences Corp. | 55.75 Million USD | 78.225% |
| uniQure N.V. | 285.08 Million USD | 95.741% |
| Imunon, Inc. | 21.03 Million USD | 42.269% |
| Blueprint Medicines Corporation | 722.86 Million USD | 98.32% |
| Insmed Incorporated | 949.26 Million USD | 98.721% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 95.944% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 97.03% |
| TG Therapeutics, Inc. | 198.47 Million USD | 93.883% |
| Incyte Corporation | 1.19 Billion USD | 98.98% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 98.837% |